Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing cancer and rare disease therapies, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 12:30 pm ET in New York. Additionally, management will join the TD Cowen 6th Annual Oncology Innovation Summit for a virtual fireside chat on May 27, 2025, at 1:30 pm ET. Both events will be webcast live and temporarily archived on the company's investor relations website.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica specializzata nello sviluppo di terapie per il cancro e le malattie rare, ha annunciato la sua partecipazione a due prossimi convegni per investitori. La società prenderà parte a una discussione informale al 3° Convegno Annuale BioConnect per Investitori di H.C. Wainwright & Co. il 20 maggio 2025 alle 12:30 ET a New York. Inoltre, il management parteciperà al 6° Summit Annuale sull'Innovazione in Oncologia di TD Cowen con una tavola rotonda virtuale il 27 maggio 2025 alle 13:30 ET. Entrambi gli eventi saranno trasmessi in diretta streaming e archiviati temporaneamente sul sito web delle relazioni con gli investitori della società.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa clínica centrada en el desarrollo de terapias para el cáncer y enfermedades raras, ha anunciado su participación en dos próximas conferencias para inversores. La compañía participará en una charla informal en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright & Co. el 20 de mayo de 2025 a las 12:30 pm ET en Nueva York. Además, la dirección participará en la 6ª Cumbre Anual de Innovación en Oncología de TD Cowen con una charla virtual el 27 de mayo de 2025 a la 1:30 pm ET. Ambos eventos serán transmitidos en vivo por internet y archivados temporalmente en el sitio web de relaciones con inversores de la compañía.
Protara Therapeutics (나스닥: TARA)는 암 및 희귀질환 치료제 개발에 주력하는 임상 단계 기업으로, 다가오는 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사는 2025년 5월 20일 뉴욕에서 동부시간 기준 오후 12시 30분에 열리는 H.C. Wainwright & Co. 제3회 연례 BioConnect 투자자 컨퍼런스에서 파이어사이드 챗에 참여할 예정입니다. 또한, 경영진은 2025년 5월 27일 동부시간 기준 오후 1시 30분에 개최되는 TD Cowen 제6회 연례 종양학 혁신 서밋의 가상 파이어사이드 챗에 참여합니다. 두 행사 모두 생중계되며 회사 투자자 관계 웹사이트에 일시적으로 아카이브됩니다.
Protara Therapeutics (Nasdaq : TARA), une société en phase clinique spécialisée dans le développement de thérapies contre le cancer et les maladies rares, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise prendra part à une discussion informelle lors de la 3e Conférence Annuelle BioConnect pour Investisseurs de H.C. Wainwright & Co. le 20 mai 2025 à 12h30 ET à New York. De plus, la direction participera à une discussion virtuelle lors du 6e Sommet Annuel d'Innovation en Oncologie de TD Cowen le 27 mai 2025 à 13h30 ET. Les deux événements seront diffusés en direct et archivés temporairement sur le site web des relations investisseurs de la société.
Protara Therapeutics (Nasdaq: TARA), ein klinisch fortgeschrittenes Unternehmen, das sich auf die Entwicklung von Therapien für Krebs und seltene Krankheiten spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 20. Mai 2025 um 12:30 Uhr ET in New York an einem Fireside-Chat auf der 3. jährlichen BioConnect-Investorenkonferenz von H.C. Wainwright & Co. teilnehmen. Zudem wird das Management am 27. Mai 2025 um 13:30 Uhr ET an einem virtuellen Fireside-Chat beim 6. jährlichen Oncology Innovation Summit von TD Cowen teilnehmen. Beide Veranstaltungen werden live übertragen und vorübergehend auf der Investor-Relations-Website des Unternehmens archiviert.
- None.
- None.
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
- H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. A fireside chat will take place on Tuesday, May 20, 2025 at 12:30 pm ET in New York.
- TD Cowen 6th Annual Oncology Innovation Summit. A fireside chat will take place virtually on Tuesday, May 27, 2025 at 1:30 pm ET.
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the H.C. Wainwright BioConnect Conference?
Where can I watch Protara Therapeutics' (TARA) investor conference presentations?
What type of company is Protara Therapeutics (TARA)?
When is Protara Therapeutics' (TARA) presentation at the TD Cowen Oncology Innovation Summit?
